Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma

Table 2 Familiar VEGFR tyrosine kinase inhibitors and their targets

TKI	VEGFR-1	VEGFR-2	VEGFR-3	Other targets
Sorafenib		+		Raf-1, B-Raf, B-Raf (V599E)
Sunitinib		+		c-Kit, FLT3, PDGFRβ
Lenvatinib	+	+	+	PDGFRα, PDGFRβ, FGFR1
Cabozantinib [19]		+		c-MET, AXL, RET, KIT, FLT3, TRKB, Tie-2
Axitinib [21, 22]	+	+	+	PDGFRα, PDGFRβ, Kit, BCR-ABL1
Vandetanib		+	+	EGFR
Dovitinib	+	+	+	c-Kit, FLT3, FGFR1
Pazopanib	+	+	+	PDGFR, FGFR, c-Kit
Foretinib	+	+	+	MET, Tie2
Apatinib		+		RET

ISSN: 1475-2867